{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:08:05Z","timestamp":1788779285545,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"crossref","award":["CSTB2024NSCQMSX0211"],"award-info":[{"award-number":["CSTB2024NSCQMSX0211"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02260-7","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:11:17Z","timestamp":1788775877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The value of fibroblast activation protein inhibitor-based radionuclide theranostics in sarcoma: a systematic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2979-648X","authenticated-orcid":false,"given":"Yihong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohua","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2260_CR1","doi-asserted-by":"crossref","unstructured":"Salaun PY, Abgral R, Malard O, et al. Good clinical practice recommendations for the use of PET\/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28\u201350.","DOI":"10.1007\/s00259-019-04553-8"},{"key":"2260_CR2","doi-asserted-by":"crossref","unstructured":"Bloem J, Krestan C, de Jonge M, et al. Soft tissue tumors in adults: ESSR-approved guidelines for diagnostic Imaging. Semin Musculoskelet Radiol. 2015;19:475\u201382.","DOI":"10.1055\/s-0035-1569251"},{"key":"2260_CR3","doi-asserted-by":"crossref","unstructured":"Benz MR, Crompton JG, Harder D. PET\/CT variants and pitfalls in bone and soft tissue sarcoma. Semin Nucl Med. 2021;51:584\u201392.","DOI":"10.1053\/j.semnuclmed.2021.06.009"},{"key":"2260_CR4","doi-asserted-by":"publisher","unstructured":"Damerell V, Pepper MS, Prince S. (2021) Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-021-00647-8.","DOI":"10.1038\/s41392-021-00647-8"},{"key":"2260_CR5","doi-asserted-by":"crossref","unstructured":"Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype\u2010specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70:200\u201329.","DOI":"10.3322\/caac.21605"},{"key":"2260_CR6","doi-asserted-by":"crossref","unstructured":"Emory CL, Montgomery CO, Potter BK, Keisch ME, Conway SA. Early complications of high-dose-rate brachytherapy in soft tissue sarcoma: a comparison with traditional external-beam radiotherapy. Clin Orthop Relat Res. 2012;470:751\u20138.","DOI":"10.1007\/s11999-011-2106-5"},{"key":"2260_CR7","doi-asserted-by":"publisher","unstructured":"Lindner T, Giesel FL, Kratochwil C, Serfling SE. (2021) Radioligands targeting fibroblast activation protein (FAP). Cancers. https:\/\/doi.org\/10.3390\/cancers13225744.","DOI":"10.3390\/cancers13225744"},{"key":"2260_CR8","doi-asserted-by":"crossref","unstructured":"Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322.","DOI":"10.2967\/jnumed.118.210443"},{"key":"2260_CR9","doi-asserted-by":"publisher","unstructured":"Xin L, Gao J, Zheng Z, et al. Fibroblast activation protein-\u03b1 as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.648187.","DOI":"10.3389\/fonc.2021.648187"},{"key":"2260_CR10","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pur\u00e9","year":"2018","unstructured":"Pur\u00e9 E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343\u201357.","journal-title":"Oncogene"},{"key":"2260_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783\u2013803.","journal-title":"Cancer Metastasis Rev"},{"key":"2260_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2967\/jnumed.121.262096","volume":"63","author":"L Kessler","year":"2022","unstructured":"Kessler L, Ferdinandus J, Hirmas N, et al. ) 68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial. J Nucl Med. 2022;63:89\u201395.","journal-title":"J Nucl Med"},{"key":"2260_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.07.002","volume":"143","author":"HJ Lim","year":"2019","unstructured":"Lim HJ, Ong CAJ, Tan JWS, Teo MCC. Utility of positron emission tomography\/computed tomography (PET\/CT) imaging in the evaluation of sarcomas: A systematic review. Crit Rev Oncol Hematol. 2019;143:1\u201313.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2260_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ctrv.2003.07.004","volume":"30","author":"E Bastiaannet","year":"2004","unstructured":"Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83\u2013101.","journal-title":"Cancer Treat Rev"},{"key":"2260_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1148\/radiol.2020203275","volume":"298","author":"Y Pang","year":"2021","unstructured":"Pang Y, Zhao L, Luo Z, et al. Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298:393\u2013402.","journal-title":"Radiology"},{"key":"2260_CR16","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1007\/s00259-022-05700-4","volume":"49","author":"B Gu","year":"2022","unstructured":"Gu B, Liu X, Wang S, et al. Head-to-head evaluation of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET\/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging. 2022;49:2889\u2013901.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiol.212430","volume":"304","author":"H Fu","year":"2022","unstructured":"Fu H, Wu J, Huang J, et al. 68Ga fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET\/CT. Radiology. 2022;304:397\u2013405.","journal-title":"Radiology"},{"key":"2260_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1053\/j.semnuclmed.2025.06.011","volume":"55","author":"KM Pabst","year":"2025","unstructured":"Pabst KM, Fendler WP, Jochheim LS, Herrmann K. The value of FAPI PET\/CT in cholangiocarcinoma and pancreatic cancer: an update. Semin Nucl Med. 2025;55:701\u20139.","journal-title":"Semin Nucl Med"},{"key":"2260_CR19","doi-asserted-by":"publisher","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. (2023) FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. https:\/\/doi.org\/10.1148\/radiol.220749","DOI":"10.1148\/radiol.220749"},{"key":"2260_CR20","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.7150\/thno.106108","volume":"15","author":"S Ruzzeh","year":"2025","unstructured":"Ruzzeh S, Abdlkadir AS, Paez D, et al. Therapeutic potential of FAPI RLT in oncology: a systematic review. Theranostics. 2025;15:4084\u2013100.","journal-title":"Theranostics"},{"key":"2260_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","volume":"55","author":"O Dohi","year":"2009","unstructured":"Dohi O, Ohtani H, Hatori M, et al. Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase\u2010IV in human bone and soft tissue tumours. Histopathology. 2009;55:432\u201340.","journal-title":"Histopathology"},{"key":"2260_CR22","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","volume":"85","author":"WJ Rerrig","year":"1988","unstructured":"Rerrig WJ, Garin-chesat P, Beresford HR, Oettgen HF, Melamedt MR, Old LJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A. 1988;85:3110\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2260_CR23","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR24","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.117.190124","volume":"58","author":"U Haberkorn","year":"2017","unstructured":"Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. The future of radioligand therapy: \u03b1, \u03b2, or both? J Nucl Med. 2017;58:1017\u20138.","journal-title":"J Nucl Med"},{"key":"2260_CR25","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2024.100744","author":"J-R Tseng","year":"2024","unstructured":"Tseng J-R, Hsu C-L, Hsieh H-H, Ho K-C, Chung Y-H, Wu C-Y. The synergy of 177Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model. Biomed J. 2024. https:\/\/doi.org\/10.1016\/j.bj.2024.100744.","journal-title":"Biomed J"},{"key":"2260_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/thno.68182","volume":"12","author":"X Wen","year":"2022","unstructured":"Wen X, Xu P, Shi M, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12:422\u201333.","journal-title":"Theranostics"},{"key":"2260_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010212","author":"J Chen","year":"2025","unstructured":"Chen J, Zhou Y, Pang Y, et al. FAP-targeted radioligand therapy with 68Ga\/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010212.","journal-title":"J Immunother Cancer"},{"key":"2260_CR29","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2967\/jnumed.123.267248","volume":"65","author":"H Lanzafame","year":"2024","unstructured":"Lanzafame H, Mavroeidi IA, Pabst KM, et al. 68Ga-fibroblast activation protein inhibitor PET\/CT improves detection of intermediate and low-grade sarcomas and identifies candidates for radiopharmaceutical therapy. J Nucl Med. 2024;65:880\u20137.","journal-title":"J Nucl Med"},{"key":"2260_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2967\/jnumed.122.264689","volume":"64","author":"N Hirmas","year":"2023","unstructured":"Hirmas N, Hamacher R, Sraieb M, et al. Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities. J Nucl Med. 2023;64:711\u20136.","journal-title":"J Nucl Med"},{"key":"2260_CR31","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Pabst KM, Kessler L, et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin Cancer Res. 2022;28:4346\u201353.","journal-title":"Clin Cancer Res"},{"key":"2260_CR32","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.2967\/jnumed.125.269572","volume":"66","author":"H Lanzafame","year":"2025","unstructured":"Lanzafame H, Heilig CE, Wardelmann E, et al. ) 90Y-FAPI-46 theranostics leads to near-complete metabolic response in 3 patients with solitary fibrous tumors. J Nucl Med. 2025;66:1378\u201384.","journal-title":"J Nucl Med"},{"key":"2260_CR33","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","volume":"49","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Bayat M, Pirayesh E, Divband G, Abolhosseini A, Akbari ME. first experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med. 2024;49:e334\u20137.","journal-title":"Clin Nucl Med"},{"key":"2260_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnumed.123.266411","volume":"65","author":"R Hamacher","year":"2024","unstructured":"Hamacher R, Pabst KM, Cheung PF, et al. Fibroblast activation protein \u03b1\u2013directed imaging and therapy of solitary fibrous tumor. J Nucl Med. 2024;65:252\u20137.","journal-title":"J Nucl Med"},{"key":"2260_CR35","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1007\/s00259-021-05374-4","volume":"48","author":"SA Koerber","year":"2021","unstructured":"Koerber SA, Finck R, Dendl K, et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:3918\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR36","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1097\/RLU.0000000000005697","volume":"50","author":"M Sakir","year":"2025","unstructured":"Sakir M, Ballal S, Rastogi S, et al. Head-to-head comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET\/CT imaging in patients with sarcoma. Clin Nucl Med. 2025;50:e271\u20139.","journal-title":"Clin Nucl Med"},{"key":"2260_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2967\/jnumed.124.268258","volume":"66","author":"R Wang","year":"2025","unstructured":"Wang R, Wang J, Xiang J, et al. Comparison of [68Ga]Ga-fibroblast activation protein Inhibitor\u201304 and [18F]FDG PET imaging for solitary fibrous tumor and preliminary application of FAP-targeted radiopharmaceutical therapy. J Nucl Med. 2025;66:585\u201391.","journal-title":"J Nucl Med"},{"key":"2260_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR39","first-page":"000","volume":"00","author":"N Raeisi","year":"2025","unstructured":"Raeisi N, Saber Tanha A, Aryana K, Shahid Sales S, Barashki S. 99mTc-FAPI-46 scintigraphy and radioligand therapy with 177Lu-FAPI-2286 in locally advanced epithelioid sarcoma. Clin Nucl Med. 2025;00:000\u2013000.","journal-title":"Clin Nucl Med"},{"key":"2260_CR40","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.2967\/jnumed.125.270186","volume":"66","author":"S Ballal","year":"2025","unstructured":"Ballal S, Sakir M, Chandekar KR, et al. Efficacy and safety of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 therapy in patients with sarcoma. J Nucl Med. 2025;66:1612\u201321.","journal-title":"J Nucl Med"},{"key":"2260_CR41","first-page":"727","volume":"63","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Fragoso Costa P, Kessler L, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. J Nucl Med. 2021;63:727\u201334.","journal-title":"J Nucl Med"},{"key":"2260_CR42","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","volume":"48","author":"C Kratochwil","year":"2021","unstructured":"Kratochwil C, Giesel FL, Rathke H, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021;48:3011\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR43","first-page":"717","volume":"44","author":"PA John","year":"2002","unstructured":"John PA, Ioannidis, Ioannidis, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med. 2002;44:717\u201324.","journal-title":"J Nucl Med"},{"key":"2260_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cpet.2023.03.001","volume":"18","author":"L Kessler","year":"2023","unstructured":"Kessler L. Fibroblast activation protein inhibitor (FAPI)-PET imaging in sarcoma. PET Clin. 2023;18:353\u20139.","journal-title":"PET Clin"},{"key":"2260_CR45","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s00259-021-05194-6","volume":"48","author":"X Zhang","year":"2021","unstructured":"Zhang X, Song W, Qin C, Liu F, Lan X. Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas. Eur J Nucl Med Mol Imaging. 2021;48:2635\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR46","doi-asserted-by":"publisher","first-page":"2480493","DOI":"10.1155\/2023\/2480493","volume":"2023","author":"JN Crane","year":"2023","unstructured":"Crane JN, Graham DS, Mona CE, et al. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023;2023:2480493. https:\/\/doi.org\/10.1155\/2023\/2480493.","journal-title":"Sarcoma"},{"key":"2260_CR47","doi-asserted-by":"publisher","first-page":"104852","DOI":"10.1016\/j.critrevonc.2025.104852","volume":"215","author":"A Bracigliano","year":"2025","unstructured":"Bracigliano A, Clemente O, Peddio A, et al. FAP-\u03b1 in soft tissue and bone sarcomas: A new potential diagnostic and therapeutic biomarker in the era of precision medicine. Crit Rev Oncol Hematol. 2025;215:104852. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104852.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2260_CR48","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","volume":"47","author":"F Kaghazchi","year":"2022","unstructured":"Kaghazchi F, Aghdam RA, Haghighi S, et al. 177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma. Clin Nucl Med. 2022;47:e243\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000004021.","journal-title":"Clin Nucl Med"},{"key":"2260_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"issue":"17","key":"2260_CR50","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/cells14171398","volume":"14","author":"O Badran","year":"2025","unstructured":"Badran O, Cohen I, Bar-Sela G. Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications. Cells. 2025;14(17):1398. https:\/\/doi.org\/10.3390\/cells14171398.","journal-title":"Cells"},{"key":"2260_CR51","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2967\/jnumed.123.266843","volume":"65","author":"J Blakkisrud","year":"2024","unstructured":"Blakkisrud J, Peterson AB, Wildermann SJ, et al. SPECT\/CT image-derived absorbed dose to red marrow correlates with hematologic toxicity in patients treated with [177Lu]Lu-DOTATATE. J Nucl Med. 2024;65:753\u201360.","journal-title":"J Nucl Med"},{"key":"2260_CR52","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1088\/0031-9155\/53\/7\/007","volume":"53","author":"SA Enger","year":"2008","unstructured":"Enger SA, Hartman T, Carlsson J, Lundqvist H. Cross-fire doses from \u03b2-emitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. Phys Med Biol. 2008;53:1909\u201320.","journal-title":"Phys Med Biol"},{"key":"2260_CR53","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","volume":"59","author":"S Poty","year":"2018","unstructured":"Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. \u03b1-Emitters for radiotherapy: from basic radiochemistry to clinical studies\u2014part 2. J Nucl Med. 2018;59:1020\u20137.","journal-title":"J Nucl Med"},{"key":"2260_CR54","doi-asserted-by":"publisher","unstructured":"Nelson BJB, Andersson JD, Wuest F, Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13010049","DOI":"10.3390\/pharmaceutics13010049"},{"key":"2260_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07390-0","author":"Z Song","year":"2025","unstructured":"Song Z, Zhang J, Qin S, et al. Targeted alpha therapy: a comprehensive analysis of the biological effects from local-regional-systemic dimensions. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07390-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"2260_CR57","first-page":"1917","volume":"65","author":"A Helisch","year":"2024","unstructured":"Helisch A, Kratochwil C, Kleist C, et al. Feasibility, tolerability, and preliminary clinical response of fractionated radiopharmaceutical therapy with 213Bi-FAPI-46: pilot experience in patients with end-stage, progressive metastatic tumors. J Nucl Med. 2024;65:1917\u201322.","journal-title":"J Nucl Med"},{"key":"2260_CR58","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","volume":"50","author":"J Millul","year":"2023","unstructured":"Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023;50:3050\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR59","doi-asserted-by":"publisher","unstructured":"Ballal S, Yadav MP, Moon ES et al. (2021) First-In-Human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph14121212","DOI":"10.3390\/ph14121212"},{"key":"2260_CR60","doi-asserted-by":"publisher","unstructured":"L\u00e4ppchen T, Bilinska A, Pilatis E et al. (2024) Tailoring fibroblast-activation protein targeting for theranostics: a comparative preclinical evaluation of the 68Ga- and 177Lu-labeled monomeric and dimeric fibroblast-activation protein inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2. Molecules. https:\/\/doi.org\/10.3390\/molecules29133093","DOI":"10.3390\/molecules29133093"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02260-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:11:23Z","timestamp":1788775883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":60,"alternative-id":["2260"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02260-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflicts of interest related to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a systematic review of published literature and does not involve any new studies with human participants or animals.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}